Skip to main content

Table 2 Determinants of the plasma aldosterone concentration and aldosterone-to-renin ratio during placebo and during ARB, during a regular sodium intake

From: Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

  Plasma aldosterone concentration Aldosterone-to-renin ratio
Placebo ARB Placebo ARB
β P-value β P-value β P-value β P-value
Age (years) 0.011 0.41 0.006 0.67 0.027 0.06 0.350 0.049
Gender (women) −0.030 0.94 0.492 0.17 0.494 0.22 0.760 0.11
BMI baseline (kg/m2) 0.009 0.81 −0.009 0.80 0.015 0.70 0.029 0.56
Serum sodium (mmol/l) 0.041 0.53 −0.086 0.13 0.034 0.64 0.260 0.74
24 h urinary sodium excretion (mmol/day) 0.001 0.85 −0.002 0.35 <0.001 0.93 −0.003 0.38
Serum potassium (mmol/l) 0.346 0.42 0.011 0.98 0.377 0.42 0.355 0.61
24 h urinary potassium excretion (mmol/day) −0.001 0.88 −0.003 0.60 <−0.001 >0.99 −0.004 0.64
LN Proteinuria (g/day) 0.078 0.75 −0.135 0.58 0.003 0.99 0.075 0.82
LN Creatinine clearance (ml/min) −1.213 0.008 −1.090 0.01 −1.215 0.02 −1.475 0.009
LN Active plasma renin concentration (ng AI/ml x h) 0.274 0.29 0.171 0.30     
  1. ARB angiotensin receptor blocker (losartan 100 mg/day), LN natural logarithm